Randomized Phase II Trial of Fulvestrant With Ribociclib Versus Physician's Choice Treatments for the Patients Who Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as First Line Treatment (CLEE011AKR06R)

▪ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment

开始日期2025-06-30

申办/合作机构

Samsung Medical Center

NCT06757634

/ Not yet recruiting临床3期

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

开始日期2025-06-30

申办/合作机构

Celcuity, Inc.

NCT06941142

/ Not yet recruiting临床1期

An Ib/III Study to Evaluate the Safety and Efficacy of Sirolimus（Albumin-bound）in Combination With Palbociclib and Fulvestrant in Patients With Advanced HR- Positive, HER2- Negative Breast Cancer

This study adopts multicenter/randomized trial design. It plans to enroll patients with HR- positive, HER2- negative advanced breast cancer who are resistant to (neo)adjuvant endocrine therapy. Dose-escalation and dose-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with palbociclib and fulvestrant in this patient population.

开始日期2025-04-30

申办/合作机构

石药集团中奇制药技术（天津）有限公司

100 项与氟维司群相关的临床结果

登录后查看更多信息

100 项与氟维司群相关的转化医学

登录后查看更多信息

100 项与氟维司群相关的专利（医药）

登录后查看更多信息

6,612

项与氟维司群相关的文献（医药）

2025-06-01·CANCER LETTERS

Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations

Article

作者: Napolitano, Fabiana ; Lin, Chang-Ching A ; Fang, Yisheng V ; Chen, Chuo ; Arteaga, Carlos L ; Uemoto, Yasuaki ; Wang, Bingnan ; Ye, Dan ; Mendiratta, Saurabh ; Hanker, Ariella B ; Li, Cheung ; Bikorimana, Emmanuel ; Chica-Parrado, Maria Rosario

FGFR1 amplification and FGFR1/2 activating mutations have been associated with antiestrogen resistance in estrogen receptor-positive (ER+) breast cancer. However, there are no approved FGFR1-targeted therapies for breast cancers harboring these alterations. In this study, we investigated the selective degradation of FGFR1/2 using the proteolysis-targeting chimera (PROTAC) DGY-09-192 as a novel therapeutic strategy in ER + breast cancers harboring FGFR1/2 somatic alterations. Treatment of ER+/FGFR1-amplified breast cancer cells and patient-derived xenografts with DGY-09-192 resulted in sustained degradation of FGFR1 in a proteasome-dependent manner and suppressed downstream signal transduction. The combination of DGY-09-192 and the ERα degrader fulvestrant resulted in complete cell growth arrest and tumor regression of ER+/FGFR1-amplified patients-derived xenografts. In addition, we tested the effect of DGY-09-192 on breast cancer cells expressing FGFR1^N546K and FGFR2^K659E hotspot kinase domain mutations as well as ER-negative breast cancer cells harboring FGFR2 gene amplification. Treatment with DGY-09-192 resulted in the degradation of mutant FGFR1/2 and blocked mutant receptor-induced signal transduction and antiestrogen resistance. Collectively, our study suggests that degradation of FGFR1/2, in combination with antiestrogens, can be leveraged as a therapeutic strategy in ER + breast cancers harboring FGFR1/2 driver alterations.

2025-06-01·TOXICOLOGY IN VITRO

Effects of 17β-estradiol and estrogen receptor subtype-specific agonists on Jurkat E6.1 T-cell leukemia cells

Article

作者: Prasanna, Vijayarengamani ; Priyanka, Hannah P ; Gour, Shaili ; Kannan, Thangamani ; Vasantharekha, Ramasamy ; Patel, Mantavya N ; Chockalingam, Ramanathan ; Hariharan, Murali M ; ThyagaRajan, Srinivasan ; Thirumalai, Anupriya ; Nair, Rahul S

BACKGROUND:

Estrogen signaling plays a crucial role in immune regulation and cancer metabolism, yet its impact on T-cell leukemia remains unclear. In hematological malignancies, estrogen receptor (ER) activation may influence metabolic shifts that affect cell survival and proliferation. This study investigates the in vitro effects of 17β-estradiol and estrogen receptor subtype-specific agonists on Jurkat E6.1 T-cell leukemia cells.

PURPOSE:

To assess how estrogen signaling influences metabolic reprogramming, inflammatory response, and survival pathways in Jurkat E6.1 cells through receptor-dependent and independent mechanisms.

METHODS:

Jurkat E6.1 cells incubated with different concentrations of 17β-estradiol (10^-12 M, 10^-10 M, 10^-8 M) or ER-α agonist 4,4',4″-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (10^-10 M, 10^-8 M, 10^-6 M) or ER-β agonist diarylproprionitrile (10^-10 M, 10^-8 M, 10^-6 M) with and without non-specific antagonist ICI 182,780 (10^-6 M). The metabolic enzyme activities of hexokinase, pyruvate kinase, and citrate synthase were measured in cell pellets, while supernatants were analyzed for IL-6 and nitric oxide (NO) production. Additionally, PI3K/Akt pathway activation was assessed by measuring p-Akt/Total Akt expression.

RESULTS:

A shift from glycolysis to oxidative phosphorylation was observed on treatment with 17β-estradiol with significant decline in hexokinase activity and a concomitant increase in activities of pyruvate kinase and citrate synthase.

CONCLUSION:

17β-estradiol mediates its effects on Jurkat E6.1 cells in vitro through receptor-subtype dependent and independent mechanisms involving metabolic enzymes (hexokinase, pyruvate kinase, citrate synthase), cytokines (IL-6), nitric oxide, and signaling molecules (p-Akt).

2025-05-01·BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis, and biological evaluation of novel PROTACs compounds with good ERα degradation ability

Article

作者: Liu, Cheng ; Yang, Xueqian ; Lou, Hongxiang ; Zhang, Tao ; Ren, Wengang ; Zheng, Xiangnan ; Dong, Xu ; Zheng, Jiaqing ; Fan, Peihong

A series of ER-PROTACs compounds were designed, synthesized and tested for their ability to degrade estrogen receptor proteins and exhibit Human breast cancer cells (MCF-7) inhibition activity. Molecular docking simulations were performed using Discovery studio. Among these compounds, QDE-003-W had the highest estrogen receptor protein degradation ability and cellular activity, with a DC₅₀ value of 95 nM, for estrogen receptor protein degradation and an IC₅₀ value of 30.2 nM for cellular activity. Furthermore, the molecular docking study revealed that the biological activity of QDE-003-W depended on its suitable linker length, which gave us some reference significance for the study of ER-PROTACs. And compared with fulvestrant, QDE-003-W exhibited more favorable pharmacokinetic (PK) characteristics. No significant adverse side effects were observed under the administration protocol, which indicates that the tested mice had excellent tolerance to both the administration method and the dosage. Such favorable PK characteristics and safety features further enhance the prospects of QDE-003-W as a viable candidate for subsequent preclinical and clinical development.

1,258

项与氟维司群相关的新闻（医药）

18 小时之前

·PRNewswire

IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight

Since its launch in 2015, it has been prescribed to more than 200,000 patients globally. The drug is currently approved for use in both men and women, expanding its market potential. Despite facing competition from other CDK4/6 inhibitors like Novartis' KISQALI and Eli Lilly's VERZENIO, IBRANCE maintains a strong position in the metastatic setting. LAS VEGAS, April 24, 2025 /PRNewswire/ -- DelveInsight's " IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of IBRANCE. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Pfizer's IBRANCE (palbociclib) Overview IBRANCE is an oral medication that inhibits CDKs 4 and 6, which are crucial regulators of the cell cycle that drive cellular progression. In the U.S., IBRANCE is approved for treating adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as a first-line endocrine therapy for postmenopausal women or men or with fulvestrant for patients whose disease has progressed after endocrine treatment. IBRANCE is currently authorized in over 90 countries and has been prescribed to more than 200,000 patients worldwide. Learn more about IBRANCE projected market size for metastatic HR+/HER2− breast cancer @ IBRANCE Market Potential The HR+ HER2- subtype is the most commonly found type of breast cancer, characterized by cancer cells that have estrogen and progesterone receptors but do not overexpress HER2. A patient's journey typically begins with the onset of concerning symptoms, leading to a comprehensive clinical evaluation and various imaging tests. DelveInsight estimates that approximately 211K new cases of HR+/HER2– breast cancer occurred in the US in 2024. CDK4/6 inhibitors currently dominate the first-line treatment market and represent a significant advancement in the management of HR+/HER2-ve breast cancer. The data from large, randomized clinical trials are both strong and consistent. While single-agent endocrine therapies have shown limited benefits in the first and subsequent treatment lines for women with ER-positive metastatic breast cancer (mBC), combination therapies have emerged as a more effective option for many patients. In recent years, the treatment landscape for HR+/HER2−ve breast cancer has been transformed with the introduction of highly active targeted therapies, including CDK4/6 inhibitors, mTOR inhibitors, PARP inhibitors, new oral SERDs, and PI3K inhibitors. These advances have expanded the range of treatment options and improved survival outcomes for these patients. The market for metastatic HR+/HER2− breast cancer in the 7MM is projected to grow during the forecast period (2025–2034) due to the introduction of several novel therapies in the market. Discover more about the metastatic HR+/HER2− breast cancer market in detail @ Metastatic HR+/HER2− Breast Cancer Market Report Emerging Competitors of IBRANCE Some of the drugs in the pipeline include Gedatolisib (Celcuity), ARV-471 (Arvinas and Pfizer), OP-1250 (Olema Pharmaceuticals), KEYTRUDA (Merck), and Rupitasertib (Evexta Bio), among others. In December 2024, Arvinas and Pfizer presented preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib among patients with locally advanced or metastatic ER+/HER2- breast cancer at the San Antonio Breast Cancer Symposium (SABCS) 2024. In December 2024, Olema Pharmaceuticals presented clinical results from the ongoing Phase Ib/II study of palazestrant in combination with ribociclib in patients with ER+/HER2- advanced or metastatic breast cancer at SABCS 2024. To know more about the number of competing drugs in development, visit @ IBRANCE Market Positioning Compared to Other Drugs Key Milestones of IBRANCE In February 2021, Pfizer Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted a U.S. Patent Term Extension (PTE) certificate for IBRANCE. This extension prolongs the validity of U.S. Patent No. RE47,739 ('739) by over four years, now lasting until March 5, 2027. In April 2019, Pfizer announced that the FDA has approved a supplemental New Drug Application (sNDA) to broaden the uses of IBRANCE in combination with an aromatase inhibitor or fulvestrant, now including men with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer. In March 2017, Pfizer Inc. revealed that the FDA has approved a supplemental New Drug Application (sNDA) for IBRANCE, its pioneering cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, following the positive outcomes from the confirmatory Phase 3 trial PALOMA-2. In September 2016, Pfizer Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive recommendation for the marketing authorization of IBRANCE® (palbociclib) in the European Union (EU). This recommendation is for its use in treating women with hormone receptor-positive, HER2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. In February 2016, Pfizer announced that the FDA has approved a new indication for IBRANCE 125mg capsules, expanding its use. The approval allows IBRANCE to be used in combination with fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in women whose disease has progressed after endocrine therapy. In February 2015, Pfizer announced that the FDA granted accelerated approval for IBRANCE in combination with letrozole to treat postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as the initial endocrine-based therapy for their metastatic disease. Discover how IBRANCE is shaping the metastatic HR+/HER2− breast cancer treatment landscape @ IBRANCE Drug IBRANCE Market Dynamics IBRANCE is a targeted therapy that has revolutionized the treatment of hormone receptor-positive, HER2-negative breast cancer, particularly in combination with aromatase inhibitors or letrozole. Developed by Pfizer, IBRANCE was one of the first CDK4/6 inhibitors approved by the FDA for metastatic breast cancer, and its approval has significantly changed the treatment landscape. The drug works by inhibiting cyclin-dependent kinases 4 and 6, which are key regulators of the cell cycle, thus preventing cancer cells from proliferating. Its market dynamics have been shaped by the growing demand for targeted therapies, as well as the increasing focus on precision medicine and improved patient outcomes. The global market for IBRANCE has been positively impacted by its proven efficacy in clinical trials and its ability to extend progression-free survival in breast cancer patients. The drug's market dominance is underpinned by its widespread acceptance and adoption by oncologists worldwide. However, competition is intensifying, with other CDK4/6 inhibitors such as VERZENIO (abemaciclib) and KISQALI (ribociclib) entering the market, offering similar benefits but with some distinct clinical profiles. This competitive landscape has led to strategic pricing and marketing strategies by Pfizer, aiming to maintain IBRANCE's market leadership while managing pressures from generic alternatives. Additionally, the evolving reimbursement landscape and regulatory policies around oncology drugs are crucial factors influencing the market dynamics. Health insurers and government healthcare programs often scrutinize the cost-effectiveness of cancer treatments, which can impact the pricing and accessibility of IBRANCE in different markets. Another factor is the rising focus on combination therapies, as IBRANCE is often used in conjunction with other drugs like letrozole, which boosts its efficacy and market potential. The shift toward personalized cancer treatment regimens is expected to continue fueling demand for CDK4/6 inhibitors like IBRANCE, especially in more advanced stages of breast cancer. In terms of geographical markets, IBRANCE has seen significant uptake in North America and Europe, where the healthcare infrastructure supports innovative cancer therapies. However, emerging markets, where the economic barriers to accessing expensive cancer treatments can be higher, present a challenge to the widespread use of IBRANCE. Pfizer's ongoing efforts to expand in these regions, through partnerships and pricing adjustments, will be key to ensuring continued growth in global market share. Overall, the IBRANCE market is poised for steady growth, driven by clinical advancements, increasing breast cancer diagnoses, and the continual push toward more targeted, effective therapies. Dive deeper to get more insight into IBRANCE's strengths & weaknesses relative to competitors @ IBRANCE Market Drug Report Table of Contents Related Reports Metastatic HR+/HER2− Breast Cancer Market Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic HR+/HER2− breast cancer companies, including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, among others. HR+/HER2− Breast Cancer Pipeline HR+/HER2− Breast Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HR+/HER2− breast cancer companies, including Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, among others. Breast Cancer Market Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key breast cancer companies including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, among others. Metastatic Breast Cancer Pipeline Metastatic Breast Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key metastatic breast cancer companies, including Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准临床3期临床1期临床结果

2025-04-24

·医脉通

贵州省卫健委副主任被查！一周前还在参加公开活动 | 医脉3分钟

今天的医疗圈发生了哪些与你有关的大事？更新、更全的医学动态3分钟一网打尽********今日关键词：徐启武教授，全球最小心脏，一次挂号管三天来源 | 医脉通作者 | 晚报君新闻60秒➤曾主刀3万多台手术！中国著名神经外科学专家徐启武教授去世@上海德济医院订阅号 2025年4月22日早晨，中国神经外科领域的卓越泰斗徐启武教授与世长辞，享年八十一岁。1967年，徐启武教授毕业于上海第二医科大学，1981年又斩获上海医科大学神经外科硕士学位。此后，他前往法国郎戈医学院与美国密歇根大学医院潜心深造。徐启武教授专注于颅底肿瘤、脑干肿瘤、脊髓肿瘤以及血管畸形等脑脊髓疾病的研究与治疗。早在20世纪90年代早中期，他便创新性地提出对脊髓髓内肿瘤和脑干肿瘤采取积极手术治疗的理念，这一理念迅速得到国内外学界的高度认可。在科研领域，由他主导的多项研究成果，屡屡荣获部市级科技进步奖与教育成果奖。从医期间，他亲自主刀完成了3万余例手术，凭借着超凡入圣的精湛医术，在疑难病症治疗领域独树一帜，赢得了“华东第一刀”的盛誉。➤全省首例！50岁男子在哈尔滨植入“全球最小心脏”@哈医大一院近日，哈医大一院医疗团队为一名患者进行人工心脏植入术+冠脉搭桥术，术后患者恢复良好。术前，该院谢宝栋教授将国内所有应用的人工心脏品种向患者家属做了介绍，家属在了解到其中一款我国纯自主研发的人工心脏重量仅90g，是目前全球体积最小、重量最轻的植入式全磁悬浮人工心脏，且患者术后长期佩戴的体外控制器、电池等体外部件重量仅800g后，决定为患者植入这款人工心脏。➤一次挂号管三天！四川二、三级公立医院，今年底100%实行@四川省卫健委近日，四川省卫生健康委制定发布了《四川省“满意度提升年”行动实施方案》，明确到2025年底，85%二级公立医院和100%三级公立医院开展分时段预约诊疗服务，30%二级公立医院和50%三级公立医院提供检查检验集中预约服务。并且要求，全省二级及以上公立医院全面落实“一次挂号管三天”服务，到2025年底，二、三级公立医院100%实行“一次挂号管三天”。鼓励全省二级及以上公立医院,面向参加基本医疗保险和商业健康保险的就诊患者实行“先诊疗后付费”便民方式和信用就医结算方式。到2025年底，除甘孜州、阿坝州外，各市（州）至少30%三级公立医院开展“先诊疗后付费”服务试点。反腐60秒➤贵州省卫健委副主任被查！一周前还在参加公开活动@“长安街知事”微信公众号据贵州省纪委监委4月23日消息，省卫健委副主任、省疾病预防控制局局长田艳涉嫌严重违纪违法，目前正接受审查调查。田艳出生于1968年5月，贵州沿河人，从贵阳中医学院针灸系针灸专业毕业后，进入铜仁市中医院，担任理疗科医师。她长期在铜仁市工作，曾任市卫计委主任，2015年4月至2021年3月担任印江县委书记，期间升任市政协副主席。据媒体报道，在印江，除了“田书记”，田艳还有一个响亮的称号——“田哥艳姐”：既是决策果敢、雷厉风行、轻伤不下火线的“田哥”，又是没有架子、爱护干部、愿和群众坐一条板凳的“艳姐”。离开印江后，她担任铜仁市委常委、万山区委书记，2023年赴省卫健委工作。直至此番被查。公开报道显示，4月17日，她还参加了一个涉及医院的签约揭牌仪式，并讲话。➤江西省卫健委原主任接受调查，主动向组织交代问题@江西省纪委监委官网据江西省纪委监委4月21日消息，江西省人大教育科学文化卫生委员会主任委员王水平涉嫌严重违纪违法，主动向组织交代问题，目前正接受江西省纪委监委纪律审查和监察调查。公开简历显示，王水平1963年8月出生，长期在江西省发改委工作，后在江西省政府、江西省商务厅、江西省宜川市等地担任要职。2019年，王水平出任江西省卫生健康委员会党组书记、主任。2023年，他改任江西省人大教育科学文化卫生委员会主任委员，至此番被查。当时，与王水平搭班子的宜春市委书记颜赣辉，此前已被查。➤一医院原院长被判四年两个月！曾“精心”套取医院伙食费@“廉洁四川”微信公众号近日，据廉洁四川介绍，2024年8月，成都市温江区第三人民医院原院长魏传峰因犯贪污罪、受贿罪，被依法判处有期徒刑四年二个月，并处罚金人民币40万元。2014年，魏传峰挂职温江区第三人民医院院长期间，他带领全院上下将医院提升至三级乙等专科医院。魏传峰将集体的业绩全归功于自己身上，变得更加飘飘然起来，作风变得更加霸道。办案人员表示，魏传峰在任时很少召开院务会，即便开会也未遵守民主集中制原则，而是直接通知某项决定，当班子成员提出不同意见，他一概不理会，大搞“一言堂”。事实证明，“一言堂”背后常常藏着“利益输送”。2017年3月，魏传峰利用医院“一把手”的职权，公然违反民主集中制原则，在医院其他班子成员有不同意见情况下，仍违规决定让医院营养膳食科科长干某某（同案处理）承包经营医院食堂。医药60秒➤国内首款！阿斯利康AKT抑制剂“卡匹色替”获批上市@国家药监局 4月18日，国家药品监督管理局（NMPA）官网显示，阿斯利康的AKT抑制剂卡匹色替片（商品名：荃科得）在国内获批上市，联合氟维司群用于治疗转移性阶段接受过至少一种内分泌治疗后疾病进展，或在辅助治疗期间或完成辅助治疗后12个月内复发的激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性且伴有一种或多种PIK3CA/AKT1/PTEN改变的局部晚期或转移性乳腺癌成人患者。卡匹色替是首个且唯一在中国获批用于PIK3CA/AKT1/PTEN改变的乳腺癌患者的AKT抑制剂，为乳腺癌患者提供了新的治疗选择。➤国家药监局批准更新诺和盈说明书，纳入心血管获益临床试验数据@人民日报健康客户端 4月21日，国家药监局批准更新诺和盈（司美格鲁肽2.4毫克）的说明书，纳入了司美格鲁肽在超重或肥胖患者中的心血管结局试验（SELECT）的数据。主要结果显示，在超重或肥胖且已确诊心血管疾病不伴有糖尿病的成人患者中，诺和盈可降低主要不良心血管事件（包括心血管死亡、非致死性急性心肌梗死、非致死性卒中）发生风险。肥胖症患者面临更高的心血管发病风险、死亡风险以及因此导致的住院风险。既往基础研究发现，以司美格鲁肽2.4毫克为代表的胰高糖素样肽-1受体激动剂（GLP-1RA），通过作用于抗动脉粥样硬化发生发展的多个环节，可改善心血管代谢风险因素。此次说明书更新，为诺和盈的显著心血管获益添加了有力的临床证据。责编｜米子封面图来源｜医脉通医改新举措发布！一地缩减行政科室23个，降低行政后勤人员薪酬，绩效分配向临床一线倾斜右手发凉、麻木、发白……他得了一种鲜有的“职业病”，没想到后面的事更可怕丨医起推理吧医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。☟戳这里，更有料！

疫苗

2025-04-23

·GlobeNewswire-Health Care

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, IL. The presentation includes the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader. Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer. Presentation details are as follows: Title: Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs. fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC): results of the global, randomized, phase 3 VERITAC-2 studyPresenting Author: Erika P. Hamilton, MD, Breast Cancer Research Program, Sarah Cannon Research InstituteAbstract Number: LBA1000Session Date, Time and Location: Saturday, May 31, 2025, 1:15 PM-4:15 PM CT in Hall B1Session Type and Title: Oral Abstract Session – Breast Cancer—Metastatic Late-breaking abstracts will be released at 7:00 am CT / 8:00 am ET on the day of the scientific presentation. Additional information can be found at www.asco.org. About VepdegestrantVepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. About ArvinasArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: vepdegestrant having the potential to provide clinically meaningful outcomes for thousands of patients with metastatic breast cancer whose tumors harbor estrogen receptor 1 mutations; Arvinas’ and Pfizer’s plans to share data from the Phase 3 VERITAC-2 clinical trial with health authorities, including to potentially support regulatory filings, as well as at medical conferences in 2025; and vepdegestrant’s development as a potential monotherapy and as part of combination therapy across multiple treatment settings for estrogen receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “look forward,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy and as part of combination therapy; whether Arvinas will be able to successfully conduct and complete development for its other product candidates, including ARV-393 and ARV-102; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release. ContactsInvestors:Jeff Boyle+1 (347) 247-5089Jeff.Boyle@arvinas.com Media:Kirsten Owens+1 (203) 584-0307Kirsten.Owens@arvinas.com

临床3期快速通道ASCO会议

100 项与氟维司群相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01161	氟维司群	L02BA03	DB00947

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
HR阳性乳腺腺癌	美国	AstraZeneca Pharmaceuticals LP	2017-08-25
乳腺癌	日本	AstraZeneca KK	2011-09-26
ER阳性乳腺癌	欧盟	AstraZeneca AB	2004-03-09
ER阳性乳腺癌	冰岛	AstraZeneca AB	2004-03-09
ER阳性乳腺癌	列支敦士登	AstraZeneca AB	2004-03-09
ER阳性乳腺癌	挪威	AstraZeneca AB	2004-03-09
HR阳性/HER2阴性乳腺癌	欧盟	AstraZeneca AB	2004-03-09
HR阳性/HER2阴性乳腺癌	冰岛	AstraZeneca AB	2004-03-09
HR阳性/HER2阴性乳腺癌	列支敦士登	AstraZeneca AB	2004-03-09
HR阳性/HER2阴性乳腺癌	挪威	AstraZeneca AB	2004-03-09
HR阳性乳腺癌	美国	AstraZeneca Pharmaceuticals LP	2002-04-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2阳性乳腺癌	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	法国	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	意大利	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	荷兰	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	西班牙	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	瑞士	Novartis Pharmaceuticals Corp.	2021-09-14
6型髓鞘减少脑白质营养不良	临床3期	意大利	Novartis Pharmaceuticals Corp.	2018-02-02
早期乳腺癌	临床3期	西班牙	AstraZeneca PLC	2007-11-01
孤立性纤维瘤	临床3期	加拿大	AstraZeneca PLC	2004-01-01
孤立性纤维瘤	临床3期	哥斯达黎加	AstraZeneca PLC	2004-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05169567 (postMONARCH, CTgov)	临床3期	HR阳性/HER2阴性乳腺癌	368	Fulvestrant+Abemaciclib (Arm A: Abemaciclib Plus Fulvestrant)	艱繭獵鏇構範醖壓遞膚(鑰膚襯範淵蓋餘餘獵選) = 艱鑰願顧齋窪襯鹽淵繭製鏇選願襯醖製願鹹夢 (艱獵齋窪顧網蓋壓鏇構, 膚獵顧網鏇醖築鹽醖鏇 ~ 鹹襯獵繭構鬱壓糧願糧) 更多	-	2025-02-27
				Placebo+Fulvestrant (Arm B: Placebo Plus Fulvestrant)	艱繭獵鏇構範醖壓遞膚(鑰膚襯範淵蓋餘餘獵選) = 築願鹹艱構願積壓繭鑰製鏇選願襯醖製願鹹夢 (艱獵齋窪顧網蓋壓鏇構, 膚範艱範廠構願繭觸積 ~ 鏇鹽築蓋齋夢糧夢壓夢) 更多
NCT04256941 (CTgov)	临床2期	转移性乳腺癌	4	Fulvestrant (Fulvestrant)	襯築壓餘願顧蓋鑰醖獵(餘鏇獵觸淵顧選觸壓網) = 製膚簾構醖艱淵範構鏇鏇襯網齋願簾衊膚醖廠 (廠襯壓鏇築獵簾構鏇構, 簾齋觸窪襯繭廠獵網獵 ~ 鏇餘鹽鏇顧築範製構膚) 更多	-	2024-12-27
				fulvestrant+ribociclib (Kisqali)+abemaciclib (verzenio)+palbociclib (Ibrance) (Continuing AI After Randomization)	襯築壓餘願顧蓋鑰醖獵(餘鏇獵觸淵顧選觸壓網) = 觸鑰遞願憲積製鑰願壓鏇襯網齋願簾衊膚醖廠 (廠襯壓鏇築獵簾構鏇構, 鹹醖繭蓋壓築觸範獵襯 ~ 構簾網憲壓齋鏇鑰衊網) 更多
NCT02491983 (PARSIFAL, CTgov)	临床2期	转移性HER2阴性乳腺癌 \| ER阳性/HER2阴性乳腺癌 \| 转移性乳腺癌	486	Letrozole+palbociclib (Arm A)	艱憲艱壓願窪遞遞簾鏇 = 選簾廠襯廠夢鹹夢網範顧醖觸襯顧窪鏇遞襯鹹 (膚淵蓋獵築顧構製構獵, 艱築積網鑰積觸築繭獵 ~ 鹽窪簾願遞鹽繭願遞廠) 更多	-	2024-12-09
				Fulvestrant+palbociclib (Arm B)	艱憲艱壓願窪遞遞簾鏇 = 願鹽積淵製襯壓範願艱顧醖觸襯顧窪鏇遞襯鹹 (膚淵蓋獵築顧構製構獵, 簾鑰獵築廠夢廠廠襯積 ~ 鬱醖膚選觸夢選壓廠築) 更多
NCT04305496 (CAPItello-291, Pubmed \| J Clin Oncol)	临床3期	PIK3CA突变/HR阳性/HER2阴性乳腺癌 PIK3CA \| AKT1 \| PTEN	708	Capivasertib 400 mg twice daily with fulvestrant	築壓顧積鏇築餘衊鬱顧(觸願壓鑰獵積齋廠積壓): HR = 0.6 (95% CI, 0.51 ~ 0.71) 更多	积极	2024-12-01
				Placebo with fulvestrant
NCT02860000 (TBCRC041, CTgov)	临床2期	局部晚期乳腺癌 \| 激素难治性乳腺癌 \| 转移性乳腺癌 ... 更多	96	Laboratory Biomarker Analysis+Alisertib (Arm I (Alisertib))	襯鏇選獵遞憲網繭壓艱(範範夢醖壓簾鬱膚壓製) = 選壓衊製艱製衊繭艱鏇鏇鹽壓壓築顧遞壓積淵 (選艱繭襯餘範鬱鹹憲鑰, 網簾顧糧遞簾築構夢鏇 ~ 壓壓選築觸衊繭構遞膚) 更多	-	2024-10-18
				Laboratory Biomarker Analysis+Alisertib+Fulvestrant (Arm II (Alisertib, Fulvestrant))	襯鏇選獵遞憲網繭壓艱(範範夢醖壓簾鬱膚壓製) = 鏇遞夢積鹽壓齋選艱遞鏇鹽壓壓築顧遞壓積淵 (選艱繭襯餘範鬱鹹憲鑰, 淵願膚鑰夢齋壓夢窪簾 ~ 選齋顧齋網製獵繭積鹽) 更多
NCT02763566 (MONARCH plus, Pubmed \| Chin Med J (Engl)) 人工标引	临床3期	HR阳性/HER2阴性乳腺癌二线 \| 一线 Hormone Receptor Positive \| HER2 Negative	-	Abemaciclib anastrozoleeroiletrozoletase inhibitor	構選淵淵鏇淵遞齋範壓(鬱鹹觸膚築窪積夢觸鬱) = 鹹膚夢網淵觸窪鏇獵襯獵鏇製艱簾網簾顧鬱艱 (鏇窪獵選廠糧鬱衊築製 )	积极	2024-10-10
				Placebo anastrozoleeroiletrozoletase inhibitor	構選淵淵鏇淵遞齋範壓(鬱鹹觸膚築窪積夢觸鬱) = 夢簾簾鹽鬱顧餘膚鑰糧獵鏇製艱簾網簾顧鬱艱 (鏇窪獵選廠糧鬱衊築製 )
NCT02028507 (PEARL \| GEICAM/2013-02 PEARL \| PEARL study, CTgov)	临床3期	转移性乳腺癌 \| HR阳性/HER2阴性乳腺癌	693	Palbociclib+Exemestane (Cohort 1: Palbociclib Plus Exemestane)	鬱齋艱觸網構顧選遞構(憲糧蓋鏇構積醖壓餘鏇) = 願鏇繭憲積蓋窪齋糧憲簾願壓鬱窪積壓蓋糧憲 (獵獵觸淵願構醖廠憲餘, 繭願壓鹹醖範繭構鏇觸 ~ 願艱積範築淵鏇鹽範醖) 更多	-	2024-09-25
				Fulvestrant+Palbociclib (Cohort 2: Palbociclib Plus Fulvestrant)	鬱齋艱觸網構顧選遞構(憲糧蓋鏇構積醖壓餘鏇) = 獵蓋築願鏇膚鏇獵蓋艱簾願壓鬱窪積壓蓋糧憲 (獵獵觸淵願構醖廠憲餘, 築齋夢壓範獵鑰選餘製 ~ 鬱夢艱鏇醖憲範構鏇廠) 更多
NCT02913430 (CTgov)	早期临床1期	转移性乳腺癌	7	Fulvestrant+Palbociclib (Fulvestrant + Palbociclib)	簾蓋願網製蓋廠顧鑰鑰(艱壓壓襯遞鹹膚觸鹽窪) = 廠獵製積構範繭繭顧製製淵遞窪顧廠襯觸鹹獵 (艱壓顧蓋遞製繭壓衊淵, 襯選鏇鹽繭膚築獵鹹醖 ~ 遞壓糧襯觸築獵範鏇築) 更多	-	2024-09-23
				Tamoxifen+Palbociclib (Tamoxifen + Palbociclib)	簾蓋願網製蓋廠顧鑰鑰(艱壓壓襯遞鹹膚觸鹽窪) = 鬱觸窪廠襯糧窪築夢鬱製淵遞窪顧廠襯觸鹹獵 (艱壓顧蓋遞製繭壓衊淵, 鹹願積顧網鬱遞鬱醖鹹 ~ 齋糧衊鬱醖鑰選鹽襯鏇) 更多
NCT05054374 (CTgov)	临床1/2期	转移性乳腺癌 \| HER2 阴性乳腺癌	6	Fulvestrant+Mirdametinib (Arm 1, Part 1 - Mirdametinib in Combination With Fulvestrant)	窪積構淵艱構廠憲遞糧(繭窪壓醖網遞窪範簾醖) = 鏇構艱鹹築廠窪廠鹽範餘膚獵簾憲製願獵憲夢 (廠築構鏇願範夢鹽積餘, 膚繭築鏇築廠觸範窪夢 ~ 積繭鑰獵獵築願願積糧) 更多	-	2024-07-09
				Fulvestrant+Mirdametinib (Arm 1, Part 2 - Mirdametinib in Combination With Fulvestrant)	窪積構淵艱構廠憲遞糧(繭窪壓醖網遞窪範簾醖) = 鹹蓋獵築襯獵鹹顧築餘餘膚獵簾憲製願獵憲夢 (廠築構鏇願範夢鹽積餘, 製淵鏇窪選製艱鑰鹹糧 ~ 窪鏇夢衊鹽鹽襯壓蓋齋) 更多
NCT02690480 (GEICAM/2014-12 FLIPPER, ASCO2024) 人工标引	临床2期	HR阳性/HER2阴性乳腺癌 TP53 Mutation \| HER2 Negative \| PIK3CA Mutation \| ... 更多	187	Fulvestrant + Palbociclib	選襯壓範願蓋鏇遞憲鹹(鹹壓獵醖遞築淵遞築築) = 網鏇壓願鹹網鑰鹽蓋餘齋構網選選窪膚遞艱顧 (願獵築艱鏇壓艱願選獵 ) 更多	积极	2024-05-24
				Fulvestrant + Placebo	選襯壓範願蓋鏇遞憲鹹(鹹壓獵醖遞築淵遞築築) = 淵製獵鹽積願膚築製築齋構網選選窪膚遞艱顧 (願獵築艱鏇壓艱願選獵 ) 更多